Your browser doesn't support javascript.
loading
Memantine in Japanese patients with moderate to severe Alzheimer's disease: meta-analysis of multiple-index responder analyses.
Okuizumi, Kaoru; Kamata, Teruyoshi; Matsui, Daiju; Saito, Kengo; Matsumoto, Takuyuki; Fukuchi, Yoshikazu.
Afiliación
  • Okuizumi K; a Daiichi Sankyo Co., Ltd ., Tokyo , Japan.
  • Kamata T; a Daiichi Sankyo Co., Ltd ., Tokyo , Japan.
  • Matsui D; a Daiichi Sankyo Co., Ltd ., Tokyo , Japan.
  • Saito K; a Daiichi Sankyo Co., Ltd ., Tokyo , Japan.
  • Matsumoto T; a Daiichi Sankyo Co., Ltd ., Tokyo , Japan.
  • Fukuchi Y; a Daiichi Sankyo Co., Ltd ., Tokyo , Japan.
Expert Opin Pharmacother ; 19(5): 425-430, 2018 Apr.
Article en En | MEDLINE | ID: mdl-29448852
BACKGROUND: Responder analyses assessing clinical worsening have attempted to clarify clinically meaningful drug efficacy enhancements in patients with Alzheimer's disease (AD). RESEARCH DESIGN AND METHODS: This was a meta-analysis of two multicenter, randomized, double-blind, parallel-group, 24-week studies of 633 Japanese patients with moderate to severe AD receiving memantine 20 mg/day (n = 318) or placebo (n = 315). The clinical trial registration number is UMIN000026013. RESULTS: Overall odds ratios (OR) for a reduced likelihood of clinical worsening (memantine versus placebo) were statistically significant on the following individual and combined rating scales: Severe Impairment Battery-Japanese version (SIB-J, OR 0.52; 95% CI: 0.37, 0.73; p = 0.0001); Behavioral Pathology in AD Rating Scale (BEHAVE-AD, OR 0.53; 95% CI: 0.37, 0.75; p = 0.0003); and SIB-J + Clinician's Interview-Based Impression of Change-plus-Japanese version (SIB-J + CIBIC-plus-J; OR 0.53; 95% CI: 0.37, 0.77; p = 0.0009). A significantly reduced risk of triple worsening was evident in the memantine versus placebo group on the combined SIB-J + CIBIC-plus-J + BEHAVE-AD rating scales (OR 0.38; 95% CI: 0.22, 0.65; p = 0.0003). CONCLUSIONS: Memantine is a viable treatment option for patients with AD presenting not only with cognitive impairment, but also with a broader range of symptoms, including the behavioral and psychological symptoms of dementia.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Memantina / Antagonistas de Aminoácidos Excitadores / Enfermedad de Alzheimer Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies / Systematic_reviews Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Expert Opin Pharmacother Asunto de la revista: FARMACOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Memantina / Antagonistas de Aminoácidos Excitadores / Enfermedad de Alzheimer Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies / Systematic_reviews Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Expert Opin Pharmacother Asunto de la revista: FARMACOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido